MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.4070
-0.0270
-6.22%
After Hours: 0.4035 -0.0035 -0.86% 19:54 03/13 EDT
OPEN
0.4469
PREV CLOSE
0.4340
HIGH
0.4598
LOW
0.4070
VOLUME
289.66K
TURNOVER
--
52 WEEK HIGH
4.930
52 WEEK LOW
0.3144
MARKET CAP
1.44M
P/E (TTM)
-0.0640
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11h ago
Weekly Report: what happened at ENSC last week (0302-0306)?
Weekly Report · 4d ago
Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series
TipRanks · 03/04 13:51
Ensysce Biosciences Outlines Plans to Sequence PF614-301 Phase 3 Timeline, Reduce Regulatory Uncertainty, Prioritize PF614 and Related Pipeline Programs, and Evaluate PF614 Commercial Opportunities
Reuters · 03/04 13:45
Ensysce Biosciences announces publication on MPAR technology
TipRanks · 03/03 13:32
Ensysce Biosciences Publishes First Clinical Manuscript On Multi-Pill Abuse Resistance Overdose Protection Technology
Benzinga · 03/03 13:03
Ensysce Biosciences reports Phase 1 clinical results for PF614-MPAR overdose-protection opioid technology
Reuters · 03/03 13:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/03 12:05
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.